Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sercan Aksoy

Showing results (1-10 of 206) with videos related to

Pageof 21
Sort By:
Pain Medicine (Malden, Mass.)|May 21, 2009
Urinary colic during low-back treatment: out of the frying pan into the fire?Bayram Kaymak, Levent Ozçakar, Sercan Aksoy
Southern Medical Journal|March 24, 2006
Lithium-associated hypothyroidism and thyroid papillary carcinoma: a case reportSercan Aksoy, Saadettin Kilickap, Mustafa Erman
World Journal of Surgical Oncology|October 15, 2003
Laryngeal Involvement of Rhabdomyosarcoma in an AdultHüseyin Abali, Sercan Aksoy, Arzu Sungur, et al.
Current Medical Research and Opinion|May 23, 2013
Cardiotoxicity of novel HER2-targeted therapiesMehmet A N Sendur, Sercan Aksoy, Kadri Altundag
Medical Oncology (Northwood, London, England)|May 3, 2013
Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metforminSercan Aksoy, Mehmet Ali Nahit Sendur, Kadri Altundag
World Journal of Gastroenterology|June 20, 2014
Hepatitis C virus reactivation in cancer patients in the era of targeted therapiesOzan Yazici, Mehmet Ali Nahit Sendur, Sercan Aksoy
Current Medical Research and Opinion|September 8, 2012
Pertuzumab in HER2-positive breast cancerMehmet A N Sendur, Sercan Aksoy, Kadri Altundag
Leukemia & Lymphoma|March 6, 2009
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysisSercan Aksoy, Omer Dizdar, Mutlu Hayran, et al.
Expert Review of Anticancer Therapy|March 13, 2025
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitorsTaha Koray Sahin, Sercan Aksoy, Deniz Can Guven
Expert Opinion on Therapeutic Targets|November 26, 2010
Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literatureCagatay Arslan, Ebru Sari, Sercan Aksoy, et al.
Pageof 21

Showing results (1-10 of 206) with videos related to

Sort By:
Pageof 21
Pain Medicine (Malden, Mass.)|May 21, 2009
Urinary colic during low-back treatment: out of the frying pan into the fire?Bayram Kaymak, Levent Ozçakar, Sercan Aksoy
Southern Medical Journal|March 24, 2006
Lithium-associated hypothyroidism and thyroid papillary carcinoma: a case reportSercan Aksoy, Saadettin Kilickap, Mustafa Erman
World Journal of Surgical Oncology|October 15, 2003
Laryngeal Involvement of Rhabdomyosarcoma in an AdultHüseyin Abali, Sercan Aksoy, Arzu Sungur, et al.
Current Medical Research and Opinion|May 23, 2013
Cardiotoxicity of novel HER2-targeted therapiesMehmet A N Sendur, Sercan Aksoy, Kadri Altundag
Medical Oncology (Northwood, London, England)|May 3, 2013
Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metforminSercan Aksoy, Mehmet Ali Nahit Sendur, Kadri Altundag
World Journal of Gastroenterology|June 20, 2014
Hepatitis C virus reactivation in cancer patients in the era of targeted therapiesOzan Yazici, Mehmet Ali Nahit Sendur, Sercan Aksoy
Current Medical Research and Opinion|September 8, 2012
Pertuzumab in HER2-positive breast cancerMehmet A N Sendur, Sercan Aksoy, Kadri Altundag
Leukemia & Lymphoma|March 6, 2009
Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysisSercan Aksoy, Omer Dizdar, Mutlu Hayran, et al.
Expert Review of Anticancer Therapy|March 13, 2025
Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitorsTaha Koray Sahin, Sercan Aksoy, Deniz Can Guven
Expert Opinion on Therapeutic Targets|November 26, 2010
Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literatureCagatay Arslan, Ebru Sari, Sercan Aksoy, et al.
Pageof 21